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Abstract:  
Objective 
To evaluate response rates and survival in adults developing post-transplant lymphoproliferative 
disorder (PTLD) following liver transplantation  
Methods 
Patients were identified retrospectively and data collected through local liver and haematology 
electronic databases and pharmacy records.  
Results 
Forty-five patients were identified. The median age at first transplant and at development of PTLD 
was 48 and 54 years respectively, with the median time from transplant to PTLD diagnosis of 56 
months. The majority of cases (76%) were monomorphic B-cell lymphomas and 36% of tumours 
were EBV positive. Treatment involved reduction in immune-suppression (RIS) in 30 (67%) with RIS 
the only treatment in 3. Ten (22%) patients were treated with rituximab alone, 13 (29%) with 
chemotherapy alone and 14 (31%) patients were treated with rituximab and chemotherapy. Twenty-
six (58%) patients achieved a complete response (CR). At a median follow-up of 27 months the 
median overall survival (OS) was 50 months Response and OS were not associated with clinical 
factors or the use of rituximab.  
Conclusion 
Outcomes reported in this study are favourable and comparable to those reported previously. The 
addition of rituximab did not appear to have improved outcomes in this series, although a significant 
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Introduction 
PTLD represent a broad spectrum of lymphoid proliferations that occur after solid organ or 
allogeneic haematopoietic stem cell transplantation (1, 2). It is the most common malignancy 
complicating solid organ transplantation (excluding non-melanoma skin cancer), accounting for 
approximately 20% of all cancers (1, 3). The majority of cases occur in the first year of transplant and 
the overall incidence of PTLD following liver transplantation is reported to be 1-4% with a higher 
incidence seen in children (2, 4-6).  
 
The risk of developing PTLD is variable and depends on the type of organ transplanted, the 
immunosuppression regimen, recipient age, time post-transplantation, ethnicity (2, 7, 8) and both 
patient and donor EBV status prior to transplant (9).  The degree of immunosuppression post 
transplant has long been considered a major determinant of the development of PTLD and the 
degree of T-cell suppression appears to be more important than the degree of overall 
immunosuppression (10, 11). The risk of PTLD tends to be lower following liver transplantation 
compared to other solid organ transplants, presumably due to the lower levels of immune 
suppression required to prevent graft rejection (2). PTLD shares common features with other 
immunodeficiency related lymphomas such as a preferential representation of non-Hodgkin 
lymphoma (NHL) versus Hodgkin lymphoma, B-cell origin, involvement of extranodal and unusual 
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The current histological classification of PTLD is described in the World Health Organisation (WHO) 
classification of haematopoietic tumours and classifies PTLD into early lesions, polymorphic and 
monomorphic PTLD. The latter is then divided into B- and T-cell lymphomas that resemble those 
occurring in the immunocompetent state (15). 
Treatment can be challenging with a higher reported rate of treatment-related death compared with 
lymphomas in the immunocompetent setting. RIS is the main stay of treatment for early and 
polymorphic PTLD but this is insufficient for treatment of most monomorphic subtypes which usually 
require treatment with combination chemotherapy (16). More recently, the monoclonal anti CD20 
antibody rituximab, has been used as first line treatment of B-cell PTLDs, reserving chemotherapy 
for those with more high-risk features or those with an incomplete response (17, 18). More novel 
cellular therapies, including EBV-specific cytotoxic T-cells (CTLs), have also been investigated and are 
in clinical development (19).  
This study from the largest liver transplant unit in the United Kingdom reports the outcome of a 
retrospective series of adult patients developing PTLD.  
 
Patients and methods 
Patients  
This retrospective study included 45 adult patients who received a liver transplant at King’s College 
Hospital, London, UK, between 1986 and 2014 and subsequently developed PTLD. Patients were 
identified through local liver and haematology electronic databases and pharmacy records. Data 
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Diagnosis and Staging 
The histological diagnosis of lymphoma was confirmed by biopsy according to the classification in 
use at the time. Prior to 2008, lymphomas were in general classified into their cell of origin, i.e. B-cell 
or T-cell, and into low, intermediate or high-grade (20). From 2008 onwards, lymphomas diagnosed 
at our institution have been classified as per the WHO classification (15). EBV status of the tumour 
was determined by in situ hybridisation assays for EBV-encoded RNA (EBER). Some patients had EBV 
PCR performed on the blood. Staging investigations included either a computed tomography (CT) 
scan of the neck, chest abdomen and pelvis or a [18F]-fluoro-2-deoxy-D-glucose positron emission 
tomography (18F-FDG-PET)-CT and bone marrow biopsy as appropriate.  
Treatment 
The management and treatment of all patients was reviewed and agreed upon by the King’s College 
Hospital lymphoma multidisciplinary meeting. If appropriate from the liver transplant perspective, 
RIS formed part of the initial treatment approach. Standard treatment at our institution for 
monomorphic PTLD has been anthracycline-containing combination chemotherapy regimens, most 
commonly 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). From 
2000, a dose of rituximab, a monoclonal anti CD20 antibody, has been added to each cycle of 
chemotherapy for patients with B-cell lymphomas. More recently, based on phase II study data, 4 
weekly doses of rituximab (375mg/m2) alone has been used as initial treatment and chemotherapy 
reserved for those not achieving a complete response (18).  
Definitions 
The primary end point was overall response rate (ORR). Secondary end points were progression-free 
survival (PFS) and OS. OS was measured from the date of diagnosis of PTLD to the date of last follow-










This article is protected by copyright. All rights reserved. 
to the date of disease relapse. Early PTLD was defined as occurring in the first 24 months post 
transplant and late after 24 months.   
Response evaluation 
Response to treatment was determined 4-6 weeks following the last cycle of chemotherapy 
according to standard criteria at the time by the treating physician (21). Response was assessed by 
CT scan in 30 (67%) patients and 18F-FDG-PET /CT in 11 (24%). In addition, based on the site of 
disease, one patient had a colonoscopy and one a gastric endoscopy as part of disease 
reassessment. Four patients died prior to response assessment  
 
Statistical analysis 
Statistical analysis was performed using GraphPad PRISM® version 5 (GraphPAD Software, San Diego, 
CA). The Kaplan-Meier method was used to construct OS and PFS curves. A p-value less than 0.05 
was considered statistically significant. 
Results: 
Patient characteristics 
During this 28 years period, 4774 liver transplants have been carried out at King’s College Hospital. 
However, around 25% of patients have been lost to follow-up as they have been discharged back to 
the care of their referring hospitals. Therefore, the incidence of PTLD in this cohort is approximately 
1%. Patient characteristics of the 45 patients are shown in Table 1. Twenty-five patients (56%) were 
male and the median age at the time of PTLD was 54 years (range 23-73 years). The median age at 
first transplant was 48 years (range 15-65 years) and 10 patients had undergone a second liver 
transplant for rejection. The most common indication for transplant was autoimmune liver disease 
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cirrhosis; 4). The median time from first transplant to development of PTLD was 56 months (range 2-
195 months) with 13 (29%) occurring in the first 2 years post transplant. The histological subtype and 
stage are shown in table 2. The majority of cases, 34 (77%), were monomorphic B-cell lymphomas. 
One patient was treated on the basis of EBV viraemia alone and therefore did not have biopsy 
proven PTLD. Tumour EBV status was available in 36 (81%) patients and was positive in 16 cases 
(44%). EBV PCR from the peripheral blood were available for 36 (81%) and 16 patients had EBV 
viraemia with a median viral load of 28044 copies/ml (range 58-1065004). Interestingly, 5 patients 
with an EBV viraemia had a tumour negative for EBV. The rate of tumour EBV positivity was not 
significantly different in those developing PTLD early (within 24 months of transplant) and those 
developing it late; 33% vs 38% respectively (p=0.8). Most patients, 29 (66%), had advanced stage 
disease (stage III/IV), with 13 (29%) having stage 4 disease, including 2 patients with 2 extra-nodal 
sites involved. Eight of 12 patients (67%) with stage 1 disease had extranodal involvement, including 
4 with small bowel involvement, 2 large bowel and 1 with involvement of the liver graft. Overall, the 
most commonly involved extranodal sites were the liver graft in 10 (22%), followed by the bone 
marrow in 7 (16%) and small bowel in 6 (13%). The immunosuppression regimen at the time of PTLD 
diagnosis is shown in table 1. 
 
Treatment 
The initial PTLD therapy is shown in Figure 1. This included RIS in 30 patients (67%). In 3 patients 
with early lesions this was the only treatment received. Three patients with stage 1 disease 
underwent surgical resection, with 1 patient receiving rituximab following surgery. One patient with 
stage 1 disease received radiotherapy alone. Thirty-eight patients (84%) required systemic anti-
cancer treatment. Thirty-three patients with monomorphic B-cell lymphoma received systemic 
treatment, which included single agent rituximab in 10 (22%) patients, combination chemotherapy 
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was CHOP in 21 patients (47%). One patient received COP due to cardiac dysfunction and inability to 
received anthracycline and 1 patient was treated with single agent vincristine. One patient had 
monomorphic PTLD consisting of cells with plasma cell differentiation lacking CD20 expression and 
was treated with bortezomib, cyclophosphamide and dexamethasone. Two patients with 
monomorphic T-cell lymphomas were treated with CHOP and IVE (ifosphamide, etoposide and 
eprirubicin) respectively. The patient with a classical Hodgkin lymphoma-type PTLD was treated with 
AVD (doxorubicin, vinblastine and dacarbazine). One patient with a high EBV viraemia received 
single agent rituximab. Two patients received EBV-specific allogeneic CTLs; one patient had a 
monomorphic PTLD with plasmacytic differentiation and the other had a monomorphic B-cell 
lymphoma and also received rituximab.  
 
Response to treatment 
The overall response rate to treatment was 76% with 26 (58%) patients achieving a CR and 8 patients 
achieving a partial response (PR). Eleven patients (24%) had progressive disease. In univariate 
analysis, response was not significantly associated with age, stage, EBV status of the tumour, or 
timing of PTLD post transplant. Use of rituximab per se was not associated with an improved 
response, however, 7 of 10 patients with monomorphic B-cell lymphoma who received single agent 
rituximab achieved a complete response and were able to avoid the use of cytotoxic chemotherapy. 
Neither patient that received CTLs had a response and neither of the patients with plasma cell 
differentiation responded to treatment.  
 
Progression free survival and overall survival 
At a median follow-up of 27 months (range 1-273), the median OS is 50 months (Figure 2A) with a 1, 
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taken into account, the 1, 3, and 5 years lymphoma-free survivals are 71%, 62%, and 58% 
respectively (Figure 2C). The median PFS for patients achieving a CR has not been reached with a 1, 3 
and 5 years PFS of 100%, 90% and 83% respectively (Figure 2B). In univariate analysis, OS was not 
significantly associated with age, stage, EBV status of the tumour, presence of EBV viraemia, graft 
involvement or timing of PTLD post transplant. In addition, neither OS nor lymphoma-free survival 
was impacted by the use of rituximab in B-cell lymphoma (Figure 2D).  
 
Of the 26 patients that achieved a CR, 5 (19%) subsequently relapsed. Four of 5 patients had 
monomorphic B-cell lymphoma and had received rituximab as part of first line treatment (3 with 
chemotherapy and 1 as single agent). One relapse occurred in a patient with monomorphic T-cell 
lymphoma. Two of five relapsed patients received single agent rituximab and achieved a second CR 
and are alive at the time of data cut-off. One patient was treated with rituximab plus platinum-based 
combination chemotherapy but did not respond and died of lymphoma. The patients with T-cell 
lymphoma was treated with 3 cycles of IVE chemotherapy and achieved a second CR but then 
subsequently relapsed again at 21 months. One patient received EBV-directed CTLs at relapsed but 
had progressive disease and died. 
 
Twenty-five patients (56%) have died; 16 from lymphoma. Other causes of death include 
chemotherapy-related in 1 (patient with Hodgkin lymphoma receiving AVD chemotherapy), graft 
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DISCUSSION: 
This retrospective series from the UK’s largest liver transplant unit demonstrates an incidence of 
PTLD following liver transplant of approximately 1%, which is at the lower end of that reported in 
prior studies (2, 4, 6). The most common indication for transplantation in this series is autoimmune 
liver disease, which is in keeping with the known higher incidence of PTLD in patients transplanted 
for autoimmune diseases. Transplantation for autoimmune disease represents only 10-15% of all 
indications for liver transplantation in our unit. The higher incidence of PTLD is likely due to the more 
intensive immune-suppression used post-transplant and may also reflect immune-suppression prior 
to transplantation either for the liver disease itself or for associated inflammatory bowel disease and 
other autoimmune conditions (6, 22, 23). Although previously it has been reported that the majority 
of PTLD cases occur early post transplant, within the first 1-2 years, more recent data suggests that 
late onset PTLD is more common (6, 24). This is in keeping with our data in which 71% of cases 
occurred beyond 24 months. However, in contrast to other series in which PTLD occurring early is 
usually EBV positive, our series shows a similar distribution of EBV positive PTLD in the early and late 
groups with the caveat that there are missing data (24, 25).  
 
Overall, the outcome for patients in our series is favourable with a median OS of 50 months and a 
lymphoma-free survival at 5 years of 58%. This is comparable to a recently published series of 32 
cases of post liver transplant PTLD occurring over a 12 year period in which the 1, 3 and 5 year 
survival was 81, 74 and 60% respectively (6). In a series of 80 patients with PTLD following all solid 
organ transplantation the 3-year OS was 62% (24). Most studies have reported a high rate of 
treatment-related death in the order of 5-30%, however, there was only one treatment death in our 
series (16-18). The outcome for those patients achieving a CR appears favourable with a 5 year PFS 
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As expected the most common histological subtype of PTLD was monomorphic B-cell lymphoma. In 
general, the prognosis of this subtype has improved with the introduction better supportive care 
(use of granulocyte stimulating factor and prophylactic antibiotics), the use of rituximab and the 
recognition that not all patients require cytotoxic chemotherapy. In the phase 2 PTLD-1 study, 70 
patients with CD20 positive lymphoma were treated sequentially with 4 doses of weekly rituximab 
followed by 4 cycles of CHOP chemotherapy. The ORR to single agent rituximab was 60% with 20% 
CR and following CHOP chemotherapy 90% (68% CR). PFS at 3 and 5 years was 69% and 66% with a 
median OS of 6.6 years. Treatment-related death was 11% (17). A follow on phase 2 study stratified 
152 patients with CD20 positive PTLD based on their response to 4 doses of rituximab. All patients 
received 4 doses of rituximab and if a CR was achieved the response was consolidated with 4 further 
doses. However, if there was an incomplete response or progressive disease patients went onto 
received 4 cycles of rituximab with CHOP chemotherapy. Twenty-five percent of patients achieved a 
CR with rituximab alone and therefore avoided chemotherapy. The ORR for all patients was 88% 
with CR in 70%. Treatment-related death occurred in 8% of patients. The median OS was 6.6 years 
with a 3 year OS of 70% (18). In our study, the use of rituximab did not in itself increase response 
rates or OS in patients with B-cell lymphoma, although these data need to be interpreted with 
caution as the patients treated with and without rituximab were diagnosed and treated in different 
decades with differing treatment approaches. For patients treated in more recent years, 7/10 
patients who received single agent rituximab achieved a CR and were able to avoid the use of 
cytotoxic chemotherapy. This may have contributed to the overall low treatment-related death and 
also confirms that immune suppression-related lymphomas may not require conventional 
anthracycline-based chemotherapy regimens since there is the opportunity to modulate the immune 
system to achieve meaningful responses. Avoidance of chemotherapy is also desirable to decrease 
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In this study, we did not identify any impact of several clinical variables on response rates or OS 
including age, stage, early or late PTLD, EBV status and graft involvement. (6, 24, 26). This is possibly 
due to sample size. We included one patient in this study who was treated with single agent 
rituximab for EBV reactivation alone with no clinical evidence of PTLD. The role of EBV monitoring 
and pre-emptive treatment in adults undergoing solid organ transplantation is controversial, given 
the lack of consensus of a threshold EBV copy number that is sufficiently sensitive and specific to 
justify treatment (27).  In general, our centre does not pre-emptively treat EBV reactivation.  
 
This study provides real-world experience of the treatment of PTLD following liver transplantation. It 
confirms that favourable outcomes can be achieved and that intensive chemotherapy regimens may 
not be required to achieve meaningful responses even in histologically aggressive tumours. 
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Table 1. Patient characteristics              n=45 (%)
  
Sex; male               25 (56)
Median age at 1st transplant, years  48 (15-65)
Median age at PTLD diagnosis, years 54 (23-73)
Median time to develop PTLD, months 56 (2-195)                       
Indications for liver transplant:  
 Primary sclerosing cholangitis 8 (18)
 Cirrhosis from chronic viral hepatitis   8 (18) 
 Cryptogenic cirrhosis     6 (13)  
 Alcoholic liver disease    5 
 Primary biliary cirrhosis    4 
 Autoimmune hepatitis     4 
       Hepatocellular carcinoma    4 
       Cirrhosis (NASH)     1 
       Acute liver failure (seronegative)   2 
       Acute liver failure- hepatitis A   1 
       Extrabiliary atresia     1 
       Acute liver failure Paracetamol overdose  1 
Second transplant for rejection                          10 (22) 
Immune-suppression 
            One drug                 9 (20) 
            Two drugs                  29 (64) 
            Three drugs                  7 (16) 
            Tacrolimus                                                                   36 (80)     
            Cyclosporine                                                                8 (18) 
            Prednisolone                                                                32 (71) 
            Mycophenolate                                                            3 (7) 
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Table 2.     Histological subtype and stage                          n=44 (%) 
 
Early lesions       3 (7) 
    Plasmacytic hyperplasia      2  
    Infectious mononucleosis-like     1  
Polymorphic PTLD        4 (9) 
Monomorphic B-cell PTLD      34 (77) 
         High-grade B-cell lymphoma                                        18 (41)  
         Diffuse large B-Cell Lymphoma                 11 (25) 
         Burkitt lymphoma      3 (7) 
         Plasma cell myeloma      2 (5) 
         Plasmacytoma-like lesion               0
Monomorphic T-cell neoplasm     2 (5%) 
         Peripheral T-cell lymphoma, NOS     1  
         Hepatosplenic T-cell lymphoma    1  
Classical Hodgkin lymphoma-type PTLD 1 (2%)
 
Tumour EBV status 
         Positive       16 (36%) 
         Negative       20 (44%) 
         Unknown      8 (18%) 
Stage at diagnosis 
 Stage I+II      15 (34%) 
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Legends 
 
Figure 1: Treatment of all 45 patients; chemo; chemotherapy, RIS; reduction of immune suppression, 
R; rituximab, CTLs; cytotoxic T-cells 
 
Figure 2: Kaplain-Meier curve of overall survival (A), PFS (B) and lymphoma-free survival (C), OS 
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